Armata Pharmaceuticals, Inc. 8-K

Summary

FDA agreement on AP-SA02’s pediatric study plan sets the regulatory framework for evaluating the treatment in children with complicated Staphylococcus aureus bacteremia (SAB). The agreement is required before a biologics license application (BLA); pediatric studies are deferred until adult safety and efficacy data are generated.

Key Figures

• Proposed pediatric program covers patients up to age 17 and consists of one multicenter, open-label study assessing safety, tolerability and clinical response.
• The adult Phase 3 study is expected to begin in H2 2026; the proposed pediatric study would follow its completion.

Investor Takeaways

• Watch for initiation and results of the adult Phase 3 study, which precede the planned pediatric study and support any future expansion of AP-SA02 into pediatric patients.